GB2282601B - Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same - Google Patents

Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same

Info

Publication number
GB2282601B
GB2282601B GB9319212A GB9319212A GB2282601B GB 2282601 B GB2282601 B GB 2282601B GB 9319212 A GB9319212 A GB 9319212A GB 9319212 A GB9319212 A GB 9319212A GB 2282601 B GB2282601 B GB 2282601B
Authority
GB
United Kingdom
Prior art keywords
antigenically
polypeptides
same
active proteins
vaccines containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9319212A
Other versions
GB9319212D0 (en
GB2282601A (en
Inventor
Michel Bublot
Wannemaeker Catherine De
Didier Colau
Philippe Roux-Salembien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solvay SA
Dimminaco AG
Original Assignee
Solvay SA
Dimminaco AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay SA, Dimminaco AG filed Critical Solvay SA
Priority to GB9319212A priority Critical patent/GB2282601B/en
Priority to GB9722558A priority patent/GB2316681B/en
Publication of GB9319212D0 publication Critical patent/GB9319212D0/en
Priority to KR1019960701359A priority patent/KR960705047A/en
Priority to JP7508961A priority patent/JPH09509562A/en
Priority to ZA946887A priority patent/ZA946887B/en
Priority to BR9407507A priority patent/BR9407507A/en
Priority to PCT/EP1994/002990 priority patent/WO1995007987A2/en
Priority to EP94926246A priority patent/EP0720654A1/en
Priority to AU76158/94A priority patent/AU7615894A/en
Priority to CA002171869A priority patent/CA2171869A1/en
Publication of GB2282601A publication Critical patent/GB2282601A/en
Priority to NO961086A priority patent/NO961086L/en
Application granted granted Critical
Publication of GB2282601B publication Critical patent/GB2282601B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
GB9319212A 1993-09-16 1993-09-16 Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same Expired - Fee Related GB2282601B (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GB9319212A GB2282601B (en) 1993-09-16 1993-09-16 Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
GB9722558A GB2316681B (en) 1993-09-16 1993-09-16 Antigenically active proteins/polypeptides and coronavirus vaccines containing the same
PCT/EP1994/002990 WO1995007987A2 (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
CA002171869A CA2171869A1 (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
ZA946887A ZA946887B (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmics and live recombinant carriers therefor
BR9407507A BR9407507A (en) 1993-09-16 1994-09-07 Co-transfection plasmid protein for co-transfection with viral DNA live recombinant vehicle against coronavirus vaccine and processes for preparing a DNA molecule and a coronavirus and FIPV cacin to protect a mammal from coronavirus infection and a FIPV feline
KR1019960701359A KR960705047A (en) 1993-09-16 1994-09-07 New Protein / Polypeptides and Cotransfection Plasmids and Biocyclic Carriers
EP94926246A EP0720654A1 (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
AU76158/94A AU7615894A (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
JP7508961A JPH09509562A (en) 1993-09-16 1994-09-07 Novel protein / polypeptide and cotransfection plasmid and recombinant live carrier thereof
NO961086A NO961086L (en) 1993-09-16 1996-03-15 New proteins / polypeptides and cotransfection plasmids and living recombinant carriers for these

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9319212A GB2282601B (en) 1993-09-16 1993-09-16 Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same

Publications (3)

Publication Number Publication Date
GB9319212D0 GB9319212D0 (en) 1993-11-03
GB2282601A GB2282601A (en) 1995-04-12
GB2282601B true GB2282601B (en) 1998-04-15

Family

ID=10742112

Family Applications (2)

Application Number Title Priority Date Filing Date
GB9319212A Expired - Fee Related GB2282601B (en) 1993-09-16 1993-09-16 Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
GB9722558A Expired - Fee Related GB2316681B (en) 1993-09-16 1993-09-16 Antigenically active proteins/polypeptides and coronavirus vaccines containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB9722558A Expired - Fee Related GB2316681B (en) 1993-09-16 1993-09-16 Antigenically active proteins/polypeptides and coronavirus vaccines containing the same

Country Status (10)

Country Link
EP (1) EP0720654A1 (en)
JP (1) JPH09509562A (en)
KR (1) KR960705047A (en)
AU (1) AU7615894A (en)
BR (1) BR9407507A (en)
CA (1) CA2171869A1 (en)
GB (2) GB2282601B (en)
NO (1) NO961086L (en)
WO (1) WO1995007987A2 (en)
ZA (1) ZA946887B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724385B1 (en) * 1994-08-29 1996-12-13 Rhone Merieux FELINE INFECTIOUS PERITONITIS VACCINE.
FR2741806B1 (en) * 1995-11-30 1998-02-20 Rhone Merieux RECOMBINANT LIVING VACCINE BASED ON TYPE 1 FELINE HERPESVIRUS, PARTICULARLY AGAINST FELIN INFECTIOUS PERITONITIS
AU3650197A (en) * 1996-07-05 1998-02-02 Vanderbilt University Mutated antibody-dependent infection enhancing domains of hiv
FR2751223B1 (en) * 1996-07-19 1998-12-04 Rhone Merieux FELIN POLYNUCLEOTIDE VACCINE FORMULA
CN1223605C (en) * 2003-05-16 2005-10-19 中国科学院微生物研究所 Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof
CN113321714B (en) * 2020-02-28 2022-12-09 深圳市亚辉龙生物科技股份有限公司 Recombinant N protein of SARS-CoV-2 and its preparation and purification method
WO2022055978A1 (en) * 2020-09-08 2022-03-17 The Trustees Of The University Of Pennsylvania Compositions and methods for reducing risk of vaccine-enhanced disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264979A1 (en) * 1986-09-05 1988-04-27 Duphar International Research B.V New antigenically active proteins and peptides, and feline infectious peritonitis virus (FIPV) vaccines
WO1992008487A1 (en) * 1990-11-14 1992-05-29 Smithkline Beecham Corporation Recombinant feline coronavirus s proteins
WO1993023422A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Compositions and methods for vaccination against coronaviruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76751A (en) * 1984-11-01 1991-04-15 American Home Prod Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies
CA2005291C (en) * 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
CA2020740A1 (en) * 1989-07-12 1991-01-13 Harry Vennema Antigenically active proteins/peptides, and feline infectious peritonitis virus (fipv)-vaccines
WO1993015762A1 (en) * 1992-02-18 1993-08-19 Parhelion Corporation Feline infectious peritonitis vaccine and method of preparation
ES2182827T3 (en) * 1992-05-08 2003-03-16 Pfizer GENE OF CANINE CROWN VIRUS AND USES OF THE SAME.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264979A1 (en) * 1986-09-05 1988-04-27 Duphar International Research B.V New antigenically active proteins and peptides, and feline infectious peritonitis virus (FIPV) vaccines
WO1992008487A1 (en) * 1990-11-14 1992-05-29 Smithkline Beecham Corporation Recombinant feline coronavirus s proteins
WO1993023422A1 (en) * 1992-05-08 1993-11-25 Smithkline Beecham Corporation Compositions and methods for vaccination against coronaviruses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D Cavanagh & T D K Brown "Advances in experimental medicine and biology", 1990, Plenum, pp 159-172 *
Journal of General Virology, Vol 71, 1990, pages 1313-1323 *
Journal of General Virology, Vol 74,1993, pages 745-749 *
Microbiol Immunol, Vol 37,No 6, 1993, pages 499-504 *

Also Published As

Publication number Publication date
EP0720654A1 (en) 1996-07-10
BR9407507A (en) 1997-01-07
WO1995007987A3 (en) 1995-06-22
GB9722558D0 (en) 1997-12-24
CA2171869A1 (en) 1995-03-23
KR960705047A (en) 1996-10-09
GB2316681B (en) 1998-04-15
GB9319212D0 (en) 1993-11-03
NO961086D0 (en) 1996-03-15
GB2316681A (en) 1998-03-04
WO1995007987A2 (en) 1995-03-23
NO961086L (en) 1996-05-09
ZA946887B (en) 1995-06-27
GB2282601A (en) 1995-04-12
JPH09509562A (en) 1997-09-30
AU7615894A (en) 1995-04-03

Similar Documents

Publication Publication Date Title
GB9518001D0 (en) Container and its application
ZA947828B (en) Vaccines
GB9013410D0 (en) Polypeptide and its use
GB9705903D0 (en) VP22 Proteins and uses thereof
AU633294B2 (en) Motilin-like polypeptide and use thereof
GB9325496D0 (en) Vaccines
GB9414833D0 (en) Polypeptide
ZA9410318B (en) Phenylmethyl hexanamides and the use thereof
ZA9410217B (en) Recombinant human thymopoietin proteins and uses therefor.
GB2282601B (en) Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
GB9314802D0 (en) Modified proteins
IL109717A0 (en) Cell surface proteins and methods for the preparation and use thereof
GB9423372D0 (en) Proteins and their uses
ZA948685B (en) Vaccines
GB9322808D0 (en) Vaccines
GB9310227D0 (en) Protein and dna
ZA902869B (en) Novel peptides,and antidementia agents containing the same
GB9122330D0 (en) Dna sequence and polypeptide
ZA949266B (en) Proteins
ZA955499B (en) Helicobacter proteins and vaccines
SG69983A1 (en) Novel peptides the preparation and use thereof
GB9022760D0 (en) Dna sequence and polypeptide
ZA9057B (en) Motilin-like polypeptide and use thereof
GB9312282D0 (en) Peptide and its use
GB9221587D0 (en) Modified proteins

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19980916